Phaseline

Targets › EPM2A

EPM2A (Laforin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Oct 2027.

Plays an important role in preventing glycogen hyperphosphorylation and the formation of insoluble aggregates, via its activity as glycogen phosphatase, and by promoting the ubiquitination of proteins involved in glycogen metabolism via its interaction with the E3 ubiquitin ligase NHLRC1/malin. Shows strong phosphatase activity towards complex carbohydrates in vitro, avoiding glycogen hyperphosphorylation which is…. (UniProt, O95278)

Open in Phaseline: the race on EPM2A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Berge MinassianION283
Antisense oligonucleotide targeting EPM2A mRNA
EPM2APhase 1Lafora DiseaseOct 2027

Conditions

Lafora Disease (1)

Modalities

other (1)

Companies

Berge Minassian (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.